Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
1don MSN
Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...
Blockbuster Keytruda makes up nearly half of Merck’s sales. That’s becoming an issue.
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Merck reported Q4 sales of $15.62 billion, surpassing estimates, with EPS at $1.72. Goldman Sachs remains bullish despite a ...
Merck ( MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its ...
BofA lowered the firm’s price target on Merck (MRK) to $112 from $118 and keeps a Buy rating on the shares. Q4 results were “decent,” but 2025 ...
Merck's latest earnings call revealed a mix of growth and pain points for the pharmaceutical giant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback